Taysha Gene Therapies, Inc.(TSHA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TSHA Taysha Gene Therapies, Inc.

Not Yet Opened 04-06 16:00:00 EDT

4.65

+0.28

+6.41%

盘后4.56

-0.09-1.94%

19:55 EDT

High4.74	Low4.47	Vol4.24M
Open4.47	D1 Closing4.37	Amplitude6.06%
Mkt Cap1.34B	Tradable Cap860.25M	Total Shares287.27M
T/O19.71M	T/O Rate2.29%	Tradable Shares185.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"TSHA","market":"US","secType":"STK","nameCN":"Taysha Gene Therapies, Inc.","latestPrice":4.65,"timestamp":1775505600000,"preClose":4.37,"halted":0,"volume":4244344,"hourTrading":{"tag":"盘后","latestPrice":4.56,"preClose":4.65,"latestTime":"19:55 EDT","volume":41533,"amount":193064.5064,"timestamp":1775519724886,"change":-0.09,"changeRate":-0.019355,"amplitude":0.025806},"delay":0,"changeRate":0.06407322654462248,"floatShares":185000000,"shares":287269885,"eps":-0.340916,"marketStatus":"Not Yet Opened","change":0.28,"latestTime":"04-06 16:00:00 EDT","open":4.47,"high":4.735,"low":4.47,"amount":19705084.314136,"amplitude":0.060641,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.340916,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1775548800000},"marketStatusCode":0,"adr":0,"listingDate":1600920000000,"exchange":"NASDAQ","adjPreClose":4.37,"preHourTrading":{"tag":"盘前","latestPrice":4.57,"preClose":4.37,"latestTime":"09:28 EDT","volume":426,"amount":1792.0600362,"timestamp":1775482080001,"change":0.2,"changeRate":0.045767,"amplitude":0.086957},"postHourTrading":{"tag":"盘后","latestPrice":4.56,"preClose":4.65,"latestTime":"19:55 EDT","volume":41533,"amount":193064.5064,"timestamp":1775519724886,"change":-0.09,"changeRate":-0.019355,"amplitude":0.025806},"volumeRatio":1.853474,"impliedVol":0.941,"impliedVolPercentile":0.504},"requestUrl":"/m/hq/s/TSHA/wiki","defaultTab":"wiki","newsList":[{"id":"2625839670","title":"Taysha Gene Therapies Is Maintained at Buy by Canaccord Genuity","url":"https://stock-news.laohu8.com/highlight/detail?id=2625839670","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625839670?lang=en_us&edition=fundamental","pubTime":"2026-04-06 23:26","pubTimestamp":1775489160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TSHA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 06, 2026 11:26 ET (15:26 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625676605","title":"Taysha Gene Therapies price target raised to $17 from $14 at Canaccord","url":"https://stock-news.laohu8.com/highlight/detail?id=2625676605","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625676605?lang=en_us&edition=fundamental","pubTime":"2026-04-06 19:09","pubTimestamp":1775473784,"startTime":"0","endTime":"0","summary":"Canaccord analyst Whitney Ijem raised the firm’s price target on Taysha Gene Therapies (TSHA) to $17 from $14 and keeps a Buy rating on the shares....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/taysha-gene-therapies-price-target-raised-to-17-from-14-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/taysha-gene-therapies-price-target-raised-to-17-from-14-at-canaccord-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624578036","title":"Taysha grants 300,000 RSUs under Nasdaq inducement plan for new hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2624578036","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624578036?lang=en_us&edition=fundamental","pubTime":"2026-04-03 20:00","pubTimestamp":1775217622,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies granted inducement equity awards to four new employees under its 2023 Inducement Plan.Awards included restricted stock units covering 300,000 shares.Stock options covered 92,400 shares with an exercise price of $4.31.RSUs vest in four equal annual installments starting on first anniversary of vesting commencement date.Options vest over four years, with 25% vesting on first anniversary.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260403:nNDL68sYzf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IE00BN0W2W23.USD","IE00B64PRP62.GBP","LU2210149790.SGD","SG9999014013.SGD","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00BGHQF748.EUR","SG9999014005.SGD","NDAQ","IE00BN0W2V16.EUR","SG9999014021.USD","IE00BKPKM429.USD","BK4585","SG9999014039.USD","LU0314104364.USD","TSHA","LU2095319765.USD","IE00B3QW5Z07.USD","BK4112","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624657963","title":"Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2624657963","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624657963?lang=en_us&edition=fundamental","pubTime":"2026-04-03 20:00","pubTimestamp":1775217600,"startTime":"0","endTime":"0","summary":"DALLAS, April  03, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/03/3267992/0/en/Taysha-Gene-Therapies-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA","CNS","BK4139","BK4135"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187246058","title":"Stock Track | Taysha Gene Therapies Soars 5.33% Intraday After Cantor Fitzgerald Issues Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1187246058","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187246058?lang=en_us&edition=fundamental","pubTime":"2026-03-25 21:32","pubTimestamp":1774445547,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies, Inc. (TSHA) saw its stock price soar by 5.33% during intraday trading on Wednesday, following a positive analyst update.The surge appears to be driven by Cantor Fitzgerald...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622107533","title":"Taysha Gene Therapies (TSHA) Receives a Buy from Cantor Fitzgerald","url":"https://stock-news.laohu8.com/highlight/detail?id=2622107533","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622107533?lang=en_us&edition=fundamental","pubTime":"2026-03-25 20:18","pubTimestamp":1774441094,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Kristen Kluska from Cantor Fitzgerald maintained a Buy rating on Taysha Gene Therapies, with a price target of $19....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/taysha-gene-therapies-tsha-receives-a-buy-from-cantor-fitzgerald-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/taysha-gene-therapies-tsha-receives-a-buy-from-cantor-fitzgerald-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TSHA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621744140","title":"Should Rett Breakthrough Status and Pivotal Trial Progress Require Action From Taysha Gene Therapies (TSHA) Investors?","url":"https://stock-news.laohu8.com/highlight/detail?id=2621744140","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621744140?lang=en_us&edition=fundamental","pubTime":"2026-03-23 05:08","pubTimestamp":1774213734,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies reported full-year 2025 results on March 19, 2026, posting US$9.77 million in sales versus US$8.33 million a year earlier, alongside a net loss of US$109 million and appointing Brad Martin as Senior Vice President, Market Access and Value in February 2026.\nAt the same time, the company highlighted clinical and regulatory progress for its Rett syndrome program TSHA-102, including FDA Breakthrough Therapy designation, written FDA alignment on pivotal trial design and...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/should-rett-breakthrough-status-and-pivotal-trial-progress-r","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/should-rett-breakthrough-status-and-pivotal-trial-progress-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TSHA","PRGS","BK4139","BK4097","LU2065732104.USD","BK4211","ISBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621717175","title":"Taysha Gene Therapies (TSHA) Receives a Buy from Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2621717175","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621717175?lang=en_us&edition=fundamental","pubTime":"2026-03-22 21:15","pubTimestamp":1774185309,"startTime":"0","endTime":"0","summary":"Wells Fargo analyst Yanan Zhu maintained a Buy rating on Taysha Gene Therapies on March 20 and set a price target of $11.00. The company’s shares c...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/taysha-gene-therapies-tsha-receives-a-buy-from-wells-fargo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/taysha-gene-therapies-tsha-receives-a-buy-from-wells-fargo-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B19Z3581.USD","BK4559","LU2236285917.USD","LU0130102774.USD","LU0070302665.USD","LU0211327993.USD","LU2461242641.AUD","LU0648001328.SGD","LU1267930490.SGD","LU0320765489.SGD","BK4588","LU0251131958.USD","LU0128525929.USD","BK4139","LU1201861249.SGD","LU1894683348.USD","LU0149725797.USD","LU1035773651.USD","LU1363072403.SGD","LU0787776722.HKD","BK4207","IE00B7SZLL34.SGD","IE00B19Z3B42.SGD","LU0289960550.SGD","LU0314106906.USD","LU0162691827.USD","LU0029864427.USD","LU0868494617.USD","LU0868494708.USD","LU1267930227.SGD","LU0106831901.USD","LU0267386448.USD","LU1668664300.SGD","BK4501","LU0742534661.SGD","LU0942090050.USD","LU0251142724.SGD","LU0256863811.USD","LU1069347547.HKD","LU0052756011.USD","LU1267930573.SGD","LU1814569148.SGD","BK4504","IE0002270589.USD","LU1894683264.USD","LU0708994859.HKD","TSHA","LU0072461881.USD","LU0048573561.USD","IE000M9KFDE8.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621874791","title":"Taysha Gene Therapies Advances Rett Program As Valuation Draws Investor Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2621874791","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621874791?lang=en_us&edition=fundamental","pubTime":"2026-03-22 03:09","pubTimestamp":1774120199,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies (NasdaqGS:TSHA) received FDA Breakthrough Therapy designation for TSHA-102 in Rett syndrome.\nThe company reported a 100% patient response rate in pivotal Phase I/II data for TSHA-102.\nRegulators aligned with Taysha on pivotal trial designs for its lead Rett syndrome program.\nTaysha added a key commercial hire as it prepares for potential TSHA-102 commercialization.\n\nTaysha Gene Therapies, trading at $4.4 per share, has been drawing attention as its 1 year return stands...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/taysha-gene-therapies-advances-rett-program-as-valuation-dra","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-tsha/taysha-gene-therapies/news/taysha-gene-therapies-advances-rett-program-as-valuation-dra","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620270120","title":"Taysha Gene Therapies Signals Momentum in Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2620270120","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620270120?lang=en_us&edition=fundamental","pubTime":"2026-03-20 08:02","pubTimestamp":1773964974,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies, Inc. (($TSHA)) has held its Q4 earnings call. Read on for the main highlights of the call. Taysha Gene Therapies’ latest ear...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/taysha-gene-therapies-signals-momentum-in-earnings-call?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/taysha-gene-therapies-signals-momentum-in-earnings-call?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620914273","title":"Taysha Gene Therapies Is Maintained at Buy by Chardan Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2620914273","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620914273?lang=en_us&edition=fundamental","pubTime":"2026-03-20 02:38","pubTimestamp":1773945480,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TSHA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 19, 2026 14:38 ET (18:38 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620273943","title":"Analysts Are Bullish on These Healthcare Stocks: Collegium Pharmaceutical (COLL), Taysha Gene Therapies (TSHA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620273943","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620273943?lang=en_us&edition=fundamental","pubTime":"2026-03-20 02:30","pubTimestamp":1773945007,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Collegium Pharmaceutical (COLL) and Taysha Gene Ther...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-collegium-pharmaceutical-coll-taysha-gene-therapies-tsha-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-collegium-pharmaceutical-coll-taysha-gene-therapies-tsha-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4588","BK4585","LU0029874061.USD","XBI","BK4007","BLSX","BK4112","BLSG","BK4137","COLL","LABU","TSHA","BK4581","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620278122","title":"Chardan Capital Sticks to Their Buy Rating for Taysha Gene Therapies (TSHA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620278122","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620278122?lang=en_us&edition=fundamental","pubTime":"2026-03-20 01:55","pubTimestamp":1773942908,"startTime":"0","endTime":"0","summary":"Chardan Capital analyst Geulah Livshits maintained a Buy rating on Taysha Gene Therapies today and set a price target of $12.00. According to TipRa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/chardan-capital-sticks-to-their-buy-rating-for-taysha-gene-therapies-tsha-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/chardan-capital-sticks-to-their-buy-rating-for-taysha-gene-therapies-tsha-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620274225","title":"Taysha Gene Therapies Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2620274225","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620274225?lang=en_us&edition=fundamental","pubTime":"2026-03-19 21:31","pubTimestamp":1773927096,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies Inc reports results for the quarter ended December 31 - Earnings SummaryTaysha Gene Therapies Inc TSHA.OQ reported a quarterly adjusted loss of 8 cents per share for the quarter ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nL8N4071MC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162677975","title":"Stock Track | Taysha Gene Therapies Soars 6.52% in Pre-market on Earnings Beat and Clinical Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=1162677975","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162677975?lang=en_us&edition=fundamental","pubTime":"2026-03-19 20:38","pubTimestamp":1773923933,"startTime":"0","endTime":"0","summary":"Taysha Gene Therapies, Inc. (TSHA) saw its stock surge 6.52% during pre-market trading on Thursday. The significant move followed the release of the company's full-year 2025 financial results and a...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620404692","title":"Taysha Gene Therapies reports 2025 EPS (34c), consensus (34c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620404692","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620404692?lang=en_us&edition=fundamental","pubTime":"2026-03-19 20:11","pubTimestamp":1773922284,"startTime":"0","endTime":"0","summary":"Reports Q4 revenue $9.77M, consensus $6.3M. As of December 31, 2025, Taysha had $319.8M in cash and cash equivalents. Expects current cash resource...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/taysha-gene-therapies-reports-2025-eps-34c-consensus-34c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/taysha-gene-therapies-reports-2025-eps-34c-consensus-34c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620240861","title":"Earnings Flash (TSHA) Taysha Gene Therapies Posts 2025 Revenue $9.8M, vs. FactSet Est of $5.9M","url":"https://stock-news.laohu8.com/highlight/detail?id=2620240861","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620240861?lang=en_us&edition=fundamental","pubTime":"2026-03-19 20:07","pubTimestamp":1773922061,"startTime":"0","endTime":"0","summary":"Earnings Flash (TSHA) Taysha Gene Therapies Posts 2025 Revenue $9.8M, vs. FactSet Est of $5.9M","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TSHA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620247231","title":"Taysha Gene Therapies FY 2025 R&D expenses rise 30.91% to USD 86.4 million, net loss widens to USD 109 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620247231","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620247231?lang=en_us&edition=fundamental","pubTime":"2026-03-19 20:02","pubTimestamp":1773921732,"startTime":"0","endTime":"0","summary":"Taysha published a full-year earnings press release reporting revenue of USD 9.77 million and a net loss of USD 109 million, or USD 0.34 per share.Research and development expenses rose 30.91% to USD 86.4 million, driven primarily by higher compensation from increased R&D headcount and higher clinical trial and GMP costs tied to REVEAL studies and BLA-enabling PPQ manufacturing initiatives.General and administrative expenses increased 16.9% to USD 33.87 million, reflecting higher compensation, legal and professional fees, and debt issuance costs related to the 2025 Trinity term loan.Cash and cash equivalents were USD 319.77 million, and the company said current cash resources are expected to fund planned operating expenses into 2028.Multiple patients have been dosed in the REVEAL pivotal trial of TSHA-102, and management said it remains on track to complete dosing in the REVEAL pivotal and ASPIRE trials in Q2 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDLbTmpv5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TSHA","BK4585","SG9999014005.SGD","BK4112","SG9999014013.SGD","IE00BN0W2W23.USD","IE00BN0W2V16.EUR","LU0314104364.USD","IE00BKPKM429.USD","BK4588","LU2210150020.SGD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4139","LU2095319765.USD","IE00BN0W2T93.GBP","SG9999014039.USD","LU2210149790.SGD","SG9999014021.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620247270","title":"Press Release: Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2620247270","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620247270?lang=en_us&edition=fundamental","pubTime":"2026-03-19 20:00","pubTimestamp":1773921600,"startTime":"0","endTime":"0","summary":"Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2 2026. Received FDA clearance to initiate ASPIRE trial in three patients aged 2 to <4 years with inclusion of >=3 months of safety data in planned BLA submission to support potential for broad label; on track to complete dosing in Q2 2026. Reached written alignment with FDA on proposed PPQ and comparability strategy for commercial TSHA-102 manufacturing to support planned BLA submission package. \"2025 was a year of significant execution for Taysha, setting the stage for what we expect to be a transformative year ahead. We are focused on completing the pivotal development of TSHA-102 and bolstering our commercial readiness efforts as we advance toward potential registration. Multiple patients have been dosed in our REVEAL pivotal trial, and we remain on track to complete dosing in the REVEAL pivotal and ASPIRE trials in the second q","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BHPRN162.USD","BK4134","LU0154245673.USD","LABU","LU1814569148.SGD","LU0149725797.USD","LU2237443978.SGD","LU0971096721.USD","LU2237443549.SGD","LU2517655374.HKD","LU2746668974.SGD","LU2517655028.SGD","LU0107464264.USD","LU0170899867.USD","IE00BKVL7J92.USD","LU2746668461.USD","BK4588","LU2362540622.SGD","LU2237443382.USD","LU2362541273.HKD","BK4139","BK4006","BK4135","CMC","LU0267386448.USD","LU2517655291.USD","TSHA","LU0882574139.USD","IE00BZ1G4Q59.USD","IE00B1BXHZ80.USD","LU1363072403.SGD","LU2237443465.HKD","CNS","LU2237443622.USD","LU2237443895.HKD","IT","LU2362541513.USD","IE00BFXG1179.USD","BK4585","LU0154245756.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620456182","title":"U.S. Earnings Preview: Before Market Open March 19","url":"https://stock-news.laohu8.com/highlight/detail?id=2620456182","media":"Dow Jones","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620456182?lang=en_us&edition=fundamental","pubTime":"2026-03-19 17:30","pubTimestamp":1773912600,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.The following companies are among those expected to report their latest financial results before the market opens.Accenture PLC's second-quarter EPS is forecast at $2.84, compared with $2.82 in the prior-year period.Darden Restaurants Inc.'s third-quarter EPS is forecast at $2.95, compared with $2.74 in the prior-year period. Adjusted EPS is forecast at $2.94.Intuitive Machines Inc.'s fourth-quarter EPS is forecast at a loss of 5 cents, compared with a loss of 1 cent in the prior-year period. Adjusted EPS is forecast at a loss of 6 cents.Aveanna Healthcare Holdings Inc.'s fourth-quarter EPS is forecast at 26 cents, compared with 14 cents in the prior-year period. Adjusted EPS is forecast at 15 cents.Taysha Gene Therapies Inc.'s fourth-quarter EPS is forecast at a loss of 10 cents, compared with a loss of 7 cents in the prior-year period.MeiraGTx Holdings PLC's fourth-quarter EPS is forecast a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0265550359.USD","IE00BFSS7M15.SGD","DRI","IE00B7KXQ091.USD","BK4533","LU0868494708.USD","LU1506573853.SGD","LU2211815571.USD","BK4602","LU0289961442.SGD","LU0511384066.AUD","SG9999004303.SGD","LU0289960550.SGD","LU0545562505.USD","BK4187","LU0323239441.USD","BK4581","ACN","IE0004445015.USD","LU0738911758.USD","LU0868494617.USD","BK4196","LU1235294995.USD","LU1366333091.USD","LU0342679015.USD","BK4561","LU0154245673.USD","LU1228905037.USD","BK4534","LU0149725797.USD","LUNR","TSHA","MGTX","IE00BFSS8Q28.SGD","LU0323240290.USD","LU1032466523.USD","LU0553294199.USD","SG9999014906.USD","AVAH","LU1823568750.SGD","SG9999018857.SGD","SG9999014898.SGD","IE00BJJMRX11.SGD","IE00BHPRN162.USD","SGXZ23171101.USD","LUNL","BK4588","SGXZ31699556.SGD","LU1585245621.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.tayshagtx.com","stockEarnings":[{"period":"1week","weight":0.0116},{"period":"1month","weight":-0.0353},{"period":"3month","weight":-0.1676},{"period":"6month","weight":-0.0819},{"period":"1year","weight":2.3106},{"period":"ytd","weight":-0.2055}],"compareEarnings":[{"period":"1week","weight":0.0166},{"period":"1month","weight":-0.036},{"period":"3month","weight":-0.04},{"period":"6month","weight":-0.02},{"period":"1year","weight":0.1617},{"period":"ytd","weight":-0.0383}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.","yearOnYearQuotes":[{"month":1,"riseRate":0,"avgChangeRate":-0.177745},{"month":2,"riseRate":0.5,"avgChangeRate":0.091899},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.104956},{"month":4,"riseRate":0.333333,"avgChangeRate":0.004074},{"month":5,"riseRate":0.4,"avgChangeRate":0.055742},{"month":6,"riseRate":0.2,"avgChangeRate":-0.029545},{"month":7,"riseRate":0.6,"avgChangeRate":0.019307},{"month":8,"riseRate":0.8,"avgChangeRate":0.75256},{"month":9,"riseRate":0.2,"avgChangeRate":-0.089587},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.04036},{"month":11,"riseRate":0.5,"avgChangeRate":0.137875},{"month":12,"riseRate":0.666667,"avgChangeRate":-0.034429}],"exchange":"NASDAQ","name":"Taysha Gene Therapies, Inc.","nameEN":"Taysha Gene Therapies, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Taysha Gene Therapies, Inc.(TSHA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Taysha Gene Therapies, Inc.(TSHA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Taysha Gene Therapies, Inc.,TSHA,Taysha Gene Therapies, Inc.股票,Taysha Gene Therapies, Inc.股票老虎,Taysha Gene Therapies, Inc.股票老虎国际,Taysha Gene Therapies, Inc.行情,Taysha Gene Therapies, Inc.股票行情,Taysha Gene Therapies, Inc.股价,Taysha Gene Therapies, Inc.股市,Taysha Gene Therapies, Inc.股票价格,Taysha Gene Therapies, Inc.股票交易,Taysha Gene Therapies, Inc.股票购买,Taysha Gene Therapies, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Taysha Gene Therapies, Inc.(TSHA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Taysha Gene Therapies, Inc.(TSHA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}